Keyword: Vanderbilt University
Scientists at Vanderbilt University found that a glutaminase inhibitor improved the anticancer activity of CAR-T cells.
An enzyme that works on leptin receptors and a receptor protein called MC3R could be anti-obesity drug targets.
Appello Pharmaceuticals raised $10.5 million to fund its glutamate-modulating Parkinson’s disease treatment licensed from Vanderbilt University.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
The week’s biotech discoveries include an insulin-related gene mutation and the news that previously ignored brain structures could govern obesity.
Mutations in a gene called KRAS are found in up to 25% of lung cancers, 45% of colon tumors and 90% of pancreatic cancers. Yet after three decades of research, no effective treatments targeting KRAS mutations have been developed. Germany’s Boehringer Ingelheim hopes to turn around that streak of bad luck via a partnership it has formed with Vanderbilt University.
An NIAID-funded team has discovered a Zika antibody that reduces mother-to-fetus transmission of the virus in pregnant mice. This research could lead to the development of vaccines or other therapeutics against the virus.
Researchers have found 110 antiviral targets and several existing drugs that may hit them using gene-trap insertional mutagenesis and a computational framework.
Recently, it has become apparent the gut microbiome can influence obesity and metabolic disorders. Researchers now show that by introducing engineered gut bacteria into mice they can protect them against obesity.
Two major academic medical centers have been given a 7-year, $26.5 million cash boost from the U.S. government to help weed out inefficiencies in clinical studies.